Results 71 to 80 of about 23,963 (194)

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Review: ‘Gimme five’: future challenges in multiple sclerosis. ECTRIMS Lecture 2009 [PDF]

, 2010
This article is based on the ECTRIMS lecture given at the 25th ECTRIMS meeting which was held in Düsseldorf, Germany, from 9 to 12 September 2009. Five challenges have been identified: (1) safeguarding the principles of medical ethics; (2) optimizing the
Bartholomaus I., Ben-Nun A., Bennett JL, Bielekova B., Bradl M., Chabas D., De Jager PL, De Jager PL, Dornmair K., Ferguson B., Flügel A., Frischer JM, Gold R., Gregersen JW, Han MH, Hohlfeld R., Hohlfeld R., Junker A., Kerschensteiner M., Kerschensteiner M., Kinoshita M., Korn T., Krishnamoorthy G., Kuhlmann T., Kümpfel T., Kümpfel T., Kümpfel T., Lennon VA, Linington C., Lock C., Mathey EK, Misgeld T., Platten M., Pollinger B., Polman CH, Reinhard Hohlfeld, Schluesener HJ, Seitz S., Sobottka B., Stadelmann C., Trapp BD, Trapp BD, Wiendl H., Wiendl H., Zipp F.   +44 more
core   +1 more source

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, EarlyView.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.

PLoS ONE, 2020
PurposeThe objective of this study was to characterize the demographic and clinical profile of RRMS patients receiving fingolimod in Spain, and to evaluate drug effectiveness and safety in clinical practice.MethodsThis observational, retrospective ...
Francisco Barrero, Javier Mallada-Frechin, María Luisa Martínez-Ginés, María Eugenia Marzo, Virginia Meca-Lallana, Guillermo Izquierdo, José Ramón Ara, Celia Oreja-Guevara, José Meca-Lallana, Lucía Forero, Irene Sánchez-Vera, María José Moreno, in representation of the MS NEXT study investigators   +12 more
doaj   +1 more source

FTY720 treatment in the convalescence period improves functional recovery and reduces reactive astrogliosis in photothrombotic stroke [PDF]

, 2013
Background: The Sphingosine-1-phosphate (S1P) signaling pathway is known to influence pathophysiological processes within the brain and the synthetic S1P analog FTY720 has been shown to provide neuroprotection in experimental models of acute stroke ...
Brunkhorst, Robert, Derouiche, Amin, Ferreirós Bouzas, Nerea, Förch, Christian, Kanaan, Nathalie, Koch, Alexander, Mirceska, Ana, Mittelbronn, Michel Guy André, Pfeilschifter, Josef Martin, Pfeilschifter, Waltraud, Steinmetz, Helmuth, Zeiner, Pia Susan   +11 more
core   +3 more sources

Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment—Real‐World Historical Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
There is a paucity of data regarding the effects of prenatal disease‐modifying therapies (DMTs) for multiple sclerosis (MS), on congenital anomalies in the offspring. Moreover, data on the association with neurodevelopmental disorders are lacking. This is an historical cohort study, within the Israeli Clalit Health Services database (2005–2024) that ...
Bar Rosh, Ofek Levi, Nili Stein, Amir Yahav, Naomi Gronich   +4 more
wiley   +1 more source

The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population

ARYA Atherosclerosis, 2017
BACKGROUND: Fingolimod (FTY-720) has shown efficacy in relapsing multiple sclerosis (MS), while some side effects of this drug have been recognized that the most important is cardiovascular side effects.
Morteza Abdar, Payam Ebrahimifar, Masoud Etemadifar   +2 more
doaj  

Cost minimisation analysis of fingolimod vs. natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis

Neurología (English Edition), 2014
Introduction: At present, there is a lack of economic assessments of second-line treatments for relapsing-recurring multiple sclerosis. The aim of this study was to compare the efficiency between fingolimod and natalizumab in Spain.
C. Crespo, G. Izquierdo, A. García-Ruiz, M. Granell, M. Brosa   +4 more
doaj   +1 more source

Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?

Neurology and Therapy, 2023
Introduction Siponimod, a potent and selective sphingosine-1-phosphate (S1P1,5) agonist, is the only therapeutic agent that has shown efficacy against disability progression, decline in cognitive processing speed, total brain volume loss, gray matter ...
Marc Bigaud, Pamela Ramseier, Sarah Tisserand, Meike Lang, Beatrice Urban, Christian Beerli, Göril Karlsson   +6 more
doaj   +1 more source

Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions [PDF]

, 2018
The oral sphingosine 1-phosphate receptor (S1PR) modulator fingolimod functionally antagonizes S1PR hereby blocking lymphocyte egress from secondary lymphoid organs to the peripheral blood circulation. This results in a reduction in peripheral lymphocyte
Derfuss, Tobias, Kappos, Ludwig, Mehling, Matthias   +2 more
core